Who
Mardi Dier
EVP and CFO
Company insider
Files Form 4 as: EVP and CFO, Madrigal Pharmaceuticals; Director, Oric Pharmaceuticals; Director, Prelude Therapeutics; CFO and CBO, Acelyrin; CFO & Executive Vice President, Ultragenyx Pharmaceutical; Director, Adamas Pharmaceuticals; EVP and CFO, Portola Pharmaceuticals.
In numbers
- Trades disclosed
- 208
- Buys
- 2
- Sells
- 29
- Bought
- $322K
- Sold
- $18.8M
- Companies
- 7
- Companies where not an officer
- 3
- First trade
- 6 Nov 2013
- Last trade
- 6 Mar 2026
- Last filed
- 6 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $69K160 at $434.20 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $35K80 at $435.32 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $35K80 at $436.69 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $18K40 at $437.65 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $279K646 at $431.94 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $17K40 at $425.08 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $179K420 at $426.86 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $34K80 at $427.85 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $69K160 at $429.00 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $17K40 at $429.58 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $52K120 at $430.90 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $279K646 at $431.94 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $17K40 at $425.08 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $179K420 at $426.86 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $34K80 at $427.85 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $69K160 at $429.00 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $17K40 at $429.58 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $52K120 at $430.90 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $50K116 at $432.56 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $69K160 at $434.20 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)MDGL · themarketsdaily.com · 20 Oct 2026Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)MDGL · manilatimes.net · 15 Oct 2026Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastMDGL · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Mardi Dier; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.